Overview

• The randomized 12-month trial involving 55 Parkinson’s dementia patients demonstrated that daily Ambroxol dosing was safe, well tolerated and achieved target brain concentrations.
• Psychiatric symptoms and GFAP biomarkers remained stable in the Ambroxol group but worsened in placebo recipients, indicating potential neuroprotective effects.
• Participants carrying high-risk GBA1 gene variants experienced measurable cognitive gains when treated with Ambroxol.
• Although Ambroxol has a decades-long safety record as a European respiratory medicine, it is not approved for any use in Canada or the United States.
• Researchers at Lawson Research Institute are preparing a larger, cognition-focused clinical trial later this year to confirm Ambroxol’s disease-modifying potential.